FDA Approves Telix's Pixclara for Brain Cancer Imaging

The U.S. FDA has approved Pixclara (floretyrosine F 18), Telix's amino acid PET drug, for imaging gliomas, a type of brain cancer. This marks the first FDA-approved FET-PET imaging agent for glioma, addressing a critical need to differentiate recurrent or progressive tumors from treatment-related changes in both adult and pediatric patients. The approval offers a new diagnostic tool for improved patient management.